This bill, HB 648-FN, mandates that health insurance providers cover glucose monitoring devices and supplies for individuals diagnosed with diabetes. It amends existing laws to require insurers to provide coverage for medically necessary outpatient self-management training, educational services, and diabetes-related equipment, including traditional blood glucose monitors and continuous glucose monitoring systems (CGMS). The bill caps the copayment for prescription insulin drugs at $30 for each 30-day supply, ensuring that this cost is not subject to any deductible. Additionally, it eliminates the need for prior authorization or referrals for endocrinology services, while requiring recipients to participate in follow-up care with their healthcare practitioners at specified intervals to maintain coverage.

The legislation also emphasizes that coverage for glucose monitoring devices and supplies will be provided without deductibles, and it specifies that such coverage will not depend on the form of treatment or frequency of insulin administration. The bill aims to enhance access to necessary monitoring tools and support for individuals with diabetes, ensuring comprehensive insurance coverage for essential diabetes management services. Overall, HB 648-FN seeks to improve the quality of care for those living with diabetes by streamlining access to critical medical supplies and services.

Statutes affected:
Introduced: 415:6-e, 415:18-f, 420-A:17-a, 420-B:8-k
HB648 text: 415:6-e, 415:18-f, 420-A:17-a, 420-B:8-k